文献速递治疗药物监测与药物基因组学特殊人群用药

一例HIV感染者经口与空肠造瘘管给予多替拉韦、替诺福韦二吡呋酯和恩曲他滨的吸收差异

Decreased Absorption of Dolutegravir and Tenofovir Disoproxil Fumarate, But Not Emtricitabine, in an HIV-Infected Patient Following Oral and Jejunostomy-Tube Administration.
PubMed 文献 · Pharmacotherapy · 2017-07-18

本病例报告描述一名晚期HIV感染患者因长期顽固性恶心呕吐需经Roux-en-Y空肠造瘘管给药,通过药代动力学评估比较口服与J管给予多替拉韦、替诺福韦二吡呋酯和恩曲他滨的吸收。结果显示J管与口服给药后多替拉韦和替诺福韦暴露相似,但恩曲他滨经J管给药暴露低38%;与HIV感染者口服参考数据相比,两种途径下多替拉韦和替诺福韦暴露分别低75-76%和55-61%。

要点

  • J管与口服给药后多替拉韦和替诺福韦暴露相似,恩曲他滨经J管给药暴露低38%。
  • 与参考数据相比,两种途径下多替拉韦和替诺福韦暴露分别低75-76%和55-61%。
  • 对潜在吸收受损患者应进行药代动力学评估以确保抗逆转录病毒治疗成功。

核心结论

  • J管与口服给药后多替拉韦和替诺福韦暴露相似,但恩曲他滨经J管给药暴露低38%。
  • 与HIV感染者口服参考数据相比,两种途径下多替拉韦和替诺福韦暴露分别低75-76%和55-61%。

研究设计与样本

  • 病例报告:一名晚期HIV感染患者,因长期顽固性恶心呕吐需经Roux-en-Y空肠造瘘管给予抗逆转录病毒药物。
  • 进行药代动力学评估,比较口服与J管给予多替拉韦、替诺福韦二吡呋酯和恩曲他滨的吸收与血浆暴露。
  • 结果与已发表的HIV感染者药代动力学数据进行比较。

主要发现

  • J管与口服给药后多替拉韦和替诺福韦暴露相似。
  • 恩曲他滨经J管给药暴露比口服低38%。
  • 与参考数据相比,两种途径下多替拉韦暴露低75-76%,替诺福韦暴露低55-61%。
  • 恩曲他滨经J管给药暴露与参考数据相似,口服给药暴露比参考数据高71%。

临床怎么用

  • 对经肠内喂养管给予抗逆转录病毒药物的患者,应考虑进行药代动力学评估以确认药物暴露充足。
  • 对潜在吸收受损患者,不应默认口服与管饲给药暴露等效,需个体化评估。

局限性

  • 单例病例报告,结果不能推广至所有HIV感染者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The use of enteral feeding tubes to administer antiretroviral medications is necessary in certain patients with human immunodeficiency virus (HIV) infection. However, adequacy of drug exposures after these administration routes are largely unknown, making dosing recommendations and the attainment of viral suppression challenging in this patient population. This report describes a patient with advanced HIV infection and a complicated medical history including long-term intractable nausea/vomiting necessitating antiretroviral medication administration via a Roux-en-Y jejunostomy (J)-tube. Pharmacokinetic assessments were performed to compare differences in antiretroviral drug absorption and plasma exposure following oral and J-tube administration of dolutegravir, tenofovir disoproxil fumarate, and emtricitabine. Results were also compared with published pharmacokinetic data in HIV-infected individuals. Exposure to dolutegravir and tenofovir were similar between J-tube and oral administration routes, whereas emtricitabine exposure was 38% lower when administered via J-tube. However, in comparison with reference data in HIV-infected individuals taking these medications orally, exposure to dolutegravir and tenofovir was 75-76% and 55-61% lower, respectively, following both routes of administration. Emtricitabine exposure was similar to and 71% higher than reference data following J-tube and oral administration, respectively. This report highlights the importance of performing pharmacokinetic assessments in patients with the potential for impaired drug absorption to ensure antiretroviral treatment success.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Brooks KM, Garrett KL, Kuriakose SS, et al. Decreased Absorption of Dolutegravir and Tenofovir Disoproxil Fumarate, But Not Emtricitabine, in an HIV-Infected Patient Following Oral and Jejunostomy-Tube Administration. Pharmacotherapy. 2017. PMID: 28556353. doi:10.1002/phar.1960

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。